BIOCLIN
ActiveBIOCLIN has been active since 1976 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €282k and a net result of €29k. Equity is growing by ~27.3% per year across the filed fiscal years. Its solvency ranks better than 55% of 9584 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2024
83
/ 100
Excellent▼ -3 vs 2023
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability51▼-49
Solvency88▲+14
Growth78=
Stability100
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €23k at 30 days acceptable
Liquidity ample (current ratio 1.96 against 1.08 in 2023), but 57% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 30-06-2025, 31 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
31 d early
2023
13 d early
2022
12 d early
2021
37 d early
2020
36 d early
2019
35 d early
← before the deadline
after the deadline →
Financials · fiscal year 2024, abbreviated schema
Equity
€282k▼ 1.7%
2023 · €287k
2018: €86k
2019: €84k
2020: €84k
2021: €92k
2022: €147k
2023: €287k
2018 → 2024
Total assets
€657k▲ 8.2%
2023 · €607k
2018: €419k
2019: €359k
2020: €304k
2021: €296k
2022: €693k
2023: €607k
2018 → 2024
Net result
€29k▼ 79.4%
2023 · €140k
2018: €6k
2019: €13k
2020: €-215
2021: €8k
2022: €56k
2023: €140k
2018 → 2024
Working capital
€188k▲ 755%
2023 · €22k
2018: €77k
2019: €56k
2020: €41k
2021: €51k
2022: €-210k
2023: €22k
2018 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Equity€84k-€92k▲ 9.3%€147k▲ 61.0%€287k▲ 94.7%€282k▼ 1.7%
Operating result€2k-€11k▲ 401%€57k▲ 439%€-21k€29k
Net result€-215-€8k€56k▲ 617%€140k▲ 150%€29k▼ 79.4%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result returns to profit in 2024: €29k after a loss of €21k in 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €657k
Fixed assets
€274k▼ 11.7%
Current assets
€383k▲ 29.0%
Equity and liabilities €657k
Equity
€282k▼ 1.7%
Provisions
€39k▼ 11.5%
Debt
€335k▲ 21.7%
The debt ratio rises from 45.4% to 51.0%: debt grows while equity shrinks.
Key figures and ratios
EBITDA
€65k▲
2023 · €15k
Cash flow
€65k▼
2023 · €176k
Solvency
43.0%▼
2023 · 47.3%
Current ratio
1.96▲
2023 · 1.08
Quick ratio
1.01▲
2023 · 0.49
Debt / equity
1.19▲
2023 · 0.96
ROE
10.2%▼
2023 · 48.6%
ROA
4.4%▼
2023 · 23.0%
Interest coverage
16.70▲
2023 · 14.60
Debt
€335k▲
2023 · €276k
Debt ≤ 1 year
€196k▼
2023 · €275k
Debt > 1 year
€132k
Income taxes
€3k▲
2023 · €542
Staff costs
€34k▼
2023 · €37k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2024 against 2023
Balance sheet
Code20232024
Assets
Total assets20/58€607k€657k▲
Fixed assets21/28€310k€274k▼
Tangible fixed assets22/27€305k€269k▼
Plant, machinery and equipment23€9k€7k▼
Furniture and vehicles24€1k€1k▼
Other tangible fixed assets26€294k€261k▼
Financial fixed assets28€5k€5k=
Current assets29/58€297k€383k▲
Stocks and contracts in progress3€163k€186k▲
Stocks30/36€163k€186k▲
Amounts receivable within one year40/41€115k€148k▲
Trade receivables40€88k€128k▲
Other amounts receivable41€27k€20k▼
Cash at bank and in hand54/58€17k€45k▲
Deferred charges and accrued income490/1€3k€3k▲
Equity and liabilities
Total equity and liabilities10/49€607k€657k▲
Equity10/15€287k€282k▼
Contributions10/11€62k€62k=
Capital10€62k€62k=
Issued capital100€62k€62k=
Revaluation surpluses12€552-
Reserves13€154k€139k▼
Non-distributable reserves130/1€12k€12k=
Legal reserve130€12k€12k=
Tax-exempt reserves132€142k€126k▼
Distributable reserves133-€552
Profit (loss) carried forward14€71k€81k▲
Provisions and deferred taxes16€45k€39k▼
Deferred taxes168€45k€39k▼
Amounts payable17/49€276k€335k▲
Amounts payable after more than one year17-€132k
Financial debts170/4-€132k
Amounts payable within one year42/48€275k€196k▼
Current portion of amounts payable after more than one year42-€14k
Trade debts44€73k€108k▲
Suppliers440/4€73k€108k▲
Advances received on contracts in progress46-€36
Taxes, remuneration and social security45€8k€5k▼
Taxes450/3€1k€616▼
Remuneration and social security454/9€6k€4k▼
Other amounts payable47/48€195k€68k▼
Accrued charges and deferred income492/3€272€8k▲
Income statement
Code20232024
Remuneration, social security and pensions62€37k€34k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€36k€36k▲
Other operating charges640/8€2k€1k▼
Gross operating margin9900€54k€100k▲
Operating profit (loss)9901€-21k€29k▲
Financial income75/76B€207k€2k▼
Recurring financial income75€2k€2k▼
Non-recurring financial income76B€205k-
Financial charges65/66B€1k€4k▲
Recurring financial charges65€1k€4k▲
Profit (loss) for the period before taxes9903€185k€27k▼
Transfer from deferred taxes780€7k€5k▼
Transfer to deferred taxes680€51k-
Income taxes67/77€542€3k▲
Profit (loss) for the period9904€140k€29k▼
Transfer from tax-exempt reserves789€20k€15k▼
Transfer to tax-exempt reserves689€154k-
Profit (loss) for the period to be appropriated9905€6k€44k▲
Appropriation of the result
Profit (loss) to be appropriated9906€71k€115k▲
Profit (loss) brought forward from the previous period14P€65k€71k▲
Profit to be distributed694/7-€34k
Directors or managers695-€34k
Social balance
Average headcount (FTE)90870.40.4=
The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2026
10-08
State Gazette act
Resignations & appointmentsGeneral meeting · Director reappointment · Permanent representative7 facts ▸
State Gazette act
Resignations & appointments
General meeting · Director reappointment · Permanent representative7 facts ▸
- General meeting, 16/06/2026
- Director reappointment, NV Lithi-Pharma (bestuurder)
- Director reappointment, BV Camba-Pharma (bestuurder)
- Director reappointment, Lien Matton (bestuurder)
- Permanent representative, Thierry Baetslé
- Permanent representative, Camille Baetslé
- Director reappointment, NV Lithi-Pharma (gedelegeerd bestuurder)
2025
30-06
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
18-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
31-12
Financial
Highest result since 2018net €140k ▲150%
Net result €140k, the highest in the series.
31-12
Financial
Equity above €200kEq €287k ▲94.7%
3 profitable years in a row build equity to €287k.
19-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-12
Financial
Equity above €100kEq €147k ▲61%
2 profitable years in a row build equity to €147k.
24-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Back to profitnet €8k
Net result €8k after one loss-making year.
25-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-12
Financial
Weakest financial yearnet €-215 ▼102%
Net result drops to €-215, the lowest in the series; recovery starts the following year.
26-06
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
25-08
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 25 days late
2018
30-08
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 30 days late
2017
10-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
2016
08-08
NBB filing
Annual accounts filed
fiscal year 2015 · abbreviated schema · 8 days late
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
under verification, no change since 2026
This board is reconstructed from a single act (26102608). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.
Camba-Pharma
CurrentDirector · since 01-02-2026 · Private limited company · perm. rep.: Camille Baetslé
Lien Matton
CurrentDirector · since 01-02-2026
LITHI - PHARMA
CurrentManaging director · since 01-02-2026 · Public limited company · perm. rep.: Thierry Baetslé
01-02-2026
Camba-Pharma: Mandate renewed as Director
01-02-2026
Lien Matton: Mandate renewed as Director
01-02-2026
LITHI - PHARMA: Mandate renewed as Managing director
01-02-2026
LITHI - PHARMA: Mandate renewed as Director
Location & real-estate footprint
Registered office, Oostende · 1 establishment unit since 1980
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Troonstraat 608400 OostendeGround area
1,596 m²
Building footprint
487 m²
Volume, LiDAR
11,585 m³
Parcel 35384A0089/00N040, Flanders · tallest building 28.3 m, ±8 floors. Linked by address, not a title deed.
1 establishment unit
BIOCLIN NV Apotheek Baetsle
since 19802.017.208.238
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 35384A0089/00N040 | Flanders | 1,596 m² | 1 · 487 m² | 28.3 m · 8 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Ownership & control
2 partiesControl over this companysits on this company's board2
1 subsidiary · 2 locations
1 subsidiary · 1 location
controls
BIOCLINBE 0416.553.335
Similar companies · same sector, comparable size
APOTHEEK TOMBAL
BE 0848.202.939
Lier · Eq €282k
APOTHEEK LUC VANDEPITTE
BE 0444.942.859
Brugge · Eq €282k
APOTHEEK VAN OVERLOOP
BE 0412.571.583
Sint-Niklaas · Eq €282k
Apotheek Vandamme
BE 0878.445.559
Roeselare · Eq €283k
Apotheek Wilderen
BE 0426.952.923
Sint-Truiden · Eq €282k
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 3,504 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPublic limited company
Founded30-10-1976
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
52310
Sources
Crossroads Bank for EnterprisesNational Bank · 48 filingsAddress and cadastre registers
Data from official sources, last processed on 11-09-2026. Scores and ratios are computed by Checked and are not a credit decision.